πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,838 results for β€œSP” Clear

  1. Gastrografin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Fecal Impaction

    phase 2 small molecule active

    1 trial

  2. Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 1 g/5 ml powder for oral suspension, Gazyvaro Placebo, Myfenax 500 mg film-coated tablets

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  3. Gecacitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    cGVHD

    phase 2 small molecule active

    1 trial

  4. Gemcitabine , Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sarcoma

    phase 2 small molecule completed

    1 trial

  5. Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, 9-ING-41, Abraxane 5 mg/ml powder for dispersion for infusion.

    ACTUATE THERAPEUTICS, INC.

    Refractory Hematologic Malignancies or Solid Tumors

    phase 2 small molecule active

    1 trial

  6. Gemcitabine 1000 mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Phase II, Open-label, Parallel 2-arm, Multi-center

    phase 2 small molecule active

    1 trial

  7. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution Γ  diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  8. Gemcitabine Oxaliplatin 5FU and Leucovorin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  9. Gemcitabine plus Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  10. Gemcitabine+5FU+Leucovorin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Disease

    phase 2 small molecule completed

    1 trial

  11. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  12. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  13. Glofitamab

    Peking University Third Hospital

    MCL

    phase 2 small molecule active

    1 trial

  14. Glofitamab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory Aggressive B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  15. Glutamine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rheumatic Heart Disease

    phase 2 small molecule completed

    1 trial

  16. GlyT-1 inhibitor-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  17. Glycosides Of Tripterygium Wilfordii Hook(GTW)

    The First People's Hospital of Lianyungang

    Henoch-SchΓΆnlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  18. GnP in combination with Ivonescimab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  19. GnRHa/ hCG/ hMG

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Azoospermia

    phase 2 small molecule active

    1 trial

  20. Green Tea Polyphenols (EGCG/ECG)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  21. Group A (FIT): Avapritinib + IA regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

    phase 2 small molecule active

    1 trial

  22. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  23. Guttmann NeuroRecovery – Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous spinal cord stimulation in the rehabilitation of chronic spinal cord injuries: a pilot study

    The George Institute

    Traumatic spinal cord injury

    phase 2 other active

    1 trial

  24. HAIC + Tislelizumab +lenvatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources